Pliant Therapeutics Inc (PLRX) - Net Assets
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has net assets worth $200.31 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($276.60 Million) and total liabilities ($76.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PLRX financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $200.31 Million |
| % of Total Assets | 72.42% |
| Annual Growth Rate | 90.28% |
| 5-Year Change | 7.43% |
| 10-Year Change | N/A |
| Growth Volatility | 67.26 |
Pliant Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Pliant Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Pliant Therapeutics Inc from 2017 to 2024. For live valuation and market cap data, see how much is Pliant Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $304.08 Million | -35.79% |
| 2023-12-31 | $473.58 Million | +51.14% |
| 2022-12-31 | $313.34 Million | +57.41% |
| 2021-12-31 | $199.06 Million | -29.68% |
| 2020-12-31 | $283.06 Million | +65171.49% |
| 2019-12-31 | $-435.00K | +50.68% |
| 2018-12-31 | $-882.00K | -126.21% |
| 2017-12-31 | $3.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pliant Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67348600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $321.00K | 0.11% |
| Other Components | $1.01 Billion | 333.40% |
| Total Equity | $304.08 Million | 100.00% |
Pliant Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Pliant Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
$68.23 Million |
|
Pylon Public Company Limited
BK:PYLON
|
$68.25 Million |
|
Gemvaxlink Co. Ltd
KQ:064800
|
$68.25 Million |
|
Inoue Rubber (Thailand) Public Company Limited
BK:IRC
|
$68.30 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
$68.21 Million |
|
Engenco Ltd
AU:EGN
|
$68.19 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
$68.19 Million |
|
Brimag -L
TA:BRMG
|
$68.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pliant Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 473,576,000 to 304,081,000, a change of -169,495,000 (-35.8%).
- Net loss of 210,304,000 reduced equity.
- New share issuances of 3,207,000 increased equity.
- Other comprehensive income decreased equity by 24,000.
- Other factors increased equity by 37,626,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-210.30 Million | -69.16% |
| Share Issuances | $3.21 Million | +1.05% |
| Other Comprehensive Income | $-24.00K | -0.01% |
| Other Changes | $37.63 Million | +12.37% |
| Total Change | $- | -35.79% |
Book Value vs Market Value Analysis
This analysis compares Pliant Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $4.16 | $1.20 | x |
| 2018-12-31 | $-0.05 | $1.20 | x |
| 2019-12-31 | $-0.01 | $1.20 | x |
| 2020-12-31 | $7.96 | $1.20 | x |
| 2021-12-31 | $5.55 | $1.20 | x |
| 2022-12-31 | $7.46 | $1.20 | x |
| 2023-12-31 | $8.07 | $1.20 | x |
| 2024-12-31 | $5.02 | $1.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pliant Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.31x
- Recent ROE (-69.16%) is above the historical average (-97.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -616.50% | 0.00% | 0.00x | 1.96x | $-20.96 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.19 Million |
| 2019 | 0.00% | -1.11% | 0.48x | 0.00x | $-587.50K |
| 2020 | -14.04% | -95.05% | 0.14x | 1.04x | $-68.05 Million |
| 2021 | -9.00% | -236.49% | 0.03x | 1.11x | $-37.81 Million |
| 2022 | -39.36% | -1273.32% | 0.03x | 1.12x | $-154.66 Million |
| 2023 | -34.07% | -10211.14% | 0.00x | 1.08x | $-208.69 Million |
| 2024 | -69.16% | 0.00% | 0.00x | 1.31x | $-240.71 Million |
Industry Comparison
This section compares Pliant Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pliant Therapeutics Inc (PLRX) | $200.31 Million | -616.50% | 0.38x | $68.21 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more